Jubilant Pharmova Stock Screener | Share Price & Fundamental Analysis
JUBLPHARMA
Pharmaceuticals
Screen Jubilant Pharmova share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹1079.10
▲
8.50 (0.79%)
Share Price BSE
₹1080.80
▲
10.60 (0.99%)
Market Cap
₹16,577.98 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
2.54
EPS (TTM)
₹52.99
Dividend Yield
0.48%
Debt to Equity
0.55
52W High
₹1236.30
52W Low
₹828.10
Operating Margin
17.00%
Profit Margin
7.83%
Revenue (TTM)
₹1,928.00
EBITDA
₹341.00
Net Income
₹151.00
Total Assets
₹12,756.00
Total Equity
₹6,239.00
Jubilant Pharmova Share Price History - Stock Screener Chart
Screen JUBLPHARMA historical share price movements with interactive charts. Analyze price trends and patterns.
Jubilant Pharmova Company Profile - Fundamental Screener
Screen Jubilant Pharmova company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for JUBLPHARMA shares.
Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and Allergy Therapy Products. It has 6 US FDA approved manufacturing facilities in India, USA and Canada, and a network of over 48 radiopharmacies in the USA. Jubilant Pharmova provides drug discovery and development services, and is working on addressing unmet medical needs in oncology and autoimmune diseases. The company has filed numerous Drug Master Files in various countries and has expanded its manufacturing and research capabilities in recent years.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Shyam S Bhartia
ISIN
INE700A01033
Website
https://www.jubl.com
Jubilant Pharmova Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen JUBLPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 12,756 | 11,549 | 11,157 | 9,991 | 8,918 | 12,522 | 11,469 | 9,618 | 9,041 | 8,824 |
| Current Assets | 3,577 | 3,876 | 3,762 | 3,509 | 2,953 | 5,038 | 4,585 | 3,190 | 2,948 | 2,875 |
| Fixed Assets | 5,176 | 5,091 | 5,183 | 4,871 | 4,609 | 6,340 | 5,648 | 5,401 | 5,107 | 5,104 |
| Liabilities | ||||||||||
| Total Liabilities | 12,756 | 11,549 | 11,157 | 9,991 | 8,918 | 12,522 | 11,469 | 9,618 | 9,041 | 8,824 |
| Current Liabilities | 4,353 | 4,238 | 3,993 | 3,083 | 3,128 | 4,299 | 4,570 | 3,578 | 3,968 | 3,432 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 6,239 | 5,421 | 5,392 | 5,316 | 4,742 | 5,604 | 4,809 | 4,035 | 3,389 | 2,928 |
| Share Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves & Surplus | 6,239 | 5,418 | 5,383 | 5,303 | 4,726 | 5,588 | 4,793 | 4,071 | 3,421 | 2,951 |
Screen JUBLPHARMA income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,928 | 1,891 | 1,968 | 1,764 | 2,130 | 1,764 | 1,823 | 1,682 | 1,575 | 1,686 | 1,714 | 1,513 | 1,452 | 1,598 | 1,543 |
| Expenses | 1,587 | 1,611 | 1,631 | 1,656 | 1,480 | 1,477 | 1,554 | 1,459 | 1,419 | 1,439 | 1,459 | 1,280 | 1,259 | 1,440 | 1,408 |
| EBITDA | 341 | 280 | 337 | 108 | 650 | 287 | 269 | 223 | 156 | 247 | 255 | 233 | 192 | 158 | 134 |
| Operating Profit % | 17.00% | 14.00% | 17.00% | 5.00% | 14.00% | 15.00% | 14.00% | 12.00% | 9.00% | 14.00% | 12.00% | 15.00% | 13.00% | 9.00% | 8.00% |
| Depreciation | 95 | 98 | 105 | 101 | 91 | 91 | 91 | 271 | 90 | 97 | 95 | 101 | 95 | 94 | 94 |
| Interest | 53 | 49 | 50 | 73 | 71 | 61 | 56 | 56 | 62 | 66 | 71 | 40 | 40 | 42 | 51 |
| Profit Before Tax | 206 | 154 | 190 | -54 | 500 | 144 | 131 | -86 | 25 | 98 | 101 | 106 | 69 | 36 | 9 |
| Tax | 55 | 52 | 70 | 8 | 18 | 42 | 30 | 14 | 19 | 36 | 35 | 47 | 22 | 32 | 25 |
| Net Profit | 151 | 103 | 120 | -62 | 482 | 103 | 101 | -101 | 6 | 62 | 66 | 59 | 47 | 5 | -16 |
| EPS | 9.71 | 6.49 | 7.59 | -3.69 | 30.44 | 6.47 | 6.37 | -6.15 | 0.40 | 3.94 | 4.22 | 3.74 | 2.96 | 0.34 | -0.98 |
Jubilant Pharmova Cash Flow Screener - Liquidity Fundamentals
Screen JUBLPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,072 | 971 | 661 | 838 | 1,784 | 1,543 | 1,122 | 1,303 | 1,269 | 1,099 |
| Investing Activities | 513 | -596 | -474 | -323 | -727 | -267 | -1,018 | -614 | -465 | -309 |
| Financing Activities | -1,453 | -433 | -157 | -33 | -1,709 | -1,050 | 657 | -901 | -686 | -843 |
| Net Cash Flow | 132 | -58 | 30 | 482 | -652 | 225 | 761 | -212 | 117 | -52 |
Screen JUBLPHARMA shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 50.68% | 47.68% | 47.68% | 50.68% | 50.68% | 50.68% | 50.68% | 50.68% |
| FII Holding | 17.22% | 17.40% | 16.57% | 19.06% | 19.49% | 17.94% | 16.96% | 0.00% |
| DII Holding | 7.05% | 9.53% | 10.52% | 3.78% | 4.07% | 5.66% | 6.98% | 0.40% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.24% |
| Public Holding | 17.75% | 17.97% | 18.02% | 18.71% | 17.79% | 18.09% | 18.09% | 18.69% |
| Other Holding | 7.31% | 7.42% | 7.22% | 7.77% | 7.97% | 7.63% | 7.30% | 28.98% |
| Shareholder Count | 96,526 | 99,673 | 93,336 | 92,264 | 81,992 | 89,456 | 102,442 | 97,935 |
Jubilant Pharmova Dividend Screener - Share Yield Analysis
Screen JUBLPHARMA dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2025-March | ₹5.00 | 0.47% |
| 2024-March | ₹5.00 | 0.56% |
| 2023-March | ₹5.00 | 0.88% |
| 2022-March | ₹5.00 | 1.79% |
| 2021-March | ₹5.00 | 1.29% |
| 2020-March | ₹5.00 | 0.73% |
| 2019-March | ₹4.50 | 1.81% |
| 2018-March | ₹3.00 | 0.45% |
| 2017-March | ₹3.00 | 0.36% |
| 2016-March | ₹0.00 | 0.00% |
Jubilant Pharmova Index Membership - Market Screener Classification
Screen JUBLPHARMA by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Jubilant Pharmova Market Events Screener - Corporate Actions
Screen JUBLPHARMA market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-10-31 | 2025-10-31 | Quarterly Result Announcement | NA | 1.90% |
| 2025-08-29 | 2025-08-29 | Annual General Meeting | NA | -7.13% |
| 2025-07-29 | 2025-07-29 | Quarterly Result Announcement | NA | -2.98% |
| 2025-07-25 | 2025-07-25 | Dividend | ₹ 5.00 /share | 29.75% |
| 2025-05-16 | 2025-05-16 | Quarterly Result Announcement | NA | 1.03% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | 1.84% |
| 2024-10-25 | 2024-10-25 | Quarterly Result Announcement | NA | -9.79% |
| 2024-08-30 | 2024-08-30 | Annual General Meeting | NA | 8.43% |
| 2024-08-02 | 2024-08-02 | Dividend | ₹ 5.00 /share | 23.06% |
| 2023-08-10 | 2023-08-10 | Dividend | ₹ 5.00 /share | 11.53% |
| 2022-08-11 | 2022-08-12 | Dividend | ₹ 5.00 /share | -11.02% |
| 2021-08-05 | 2021-08-06 | Dividend | ₹ 5.00 /share | -22.02% |
| 2021-02-01 | 2021-02-01 | Change Of Name | NA | 0.00% |
Jubilant Pharmova Competitors Screener - Peer Comparison
Screen JUBLPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,734 | 39.30 | 54,729 | 9.71% | 10,980 | 39.06 |
| Divis Laboratories | 168,851 | 68.25 | 9,712 | 18.67% | 2,191 | 44.96 |
| Torrent Pharmaceuticals | 129,357 | 59.98 | 11,539 | 6.99% | 1,911 | 59.35 |
| Cipla | 120,557 | 22.21 | 28,410 | 7.12% | 5,291 | 42.76 |
| Dr Reddys Laboratories | 105,645 | 18.46 | 33,741 | 16.73% | 5,725 | 49.97 |
| Lupin | 95,023 | 21.85 | 22,910 | 13.74% | 3,306 | 50.10 |
| Zydus Life Science | 90,707 | 18.09 | 23,511 | 18.55% | 4,615 | 34.06 |
| Mankind Pharma | 88,846 | 50.78 | 12,744 | 20.90% | 2,007 | 40.67 |
| Aurobindo Pharma | 68,901 | 20.36 | 32,346 | 9.43% | 3,484 | 46.33 |
| Alkem Laboratories | 65,390 | 27.28 | 13,458 | 3.70% | 2,216 | 37.45 |
Jubilant Pharmova Company Announcements - News Screener
Screen JUBLPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-07 | Announcement under Regulation 30 (LODR)-Acquisition | View |
| 2026-01-06 | Closure of Trading Window | View |
| 2026-01-04 | Jubilant Generics Limited - Order Passed By The Assistant Commissioner Central GST Division Roorkee | View |
| 2025-12-05 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015- Receipt Of Adjudication Order_GST | View |
| 2025-12-02 | Report On Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares | View |
| 2025-12-02 | Appointment Of Mr. Daniel J. OConnor As CEO Of Jubilant Therapeutics Inc. | View |
| 2025-11-28 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-08 | Submission Of Communication Email Sent To Shareholders Whose Dividend(S) Remains Unpaid Pursuant To "Saksham Niveshak - 100 Days Campaign" | View |
| 2025-11-04 | USFDA Communication Montreal Canada | View |
| 2025-11-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-31 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-10-31 | Approval For Grant Of Stock Options/Rsus | View |
| 2025-10-31 | Un-Audited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-10-31 | Board Meeting Outcome for Meeting Held On October 31 2025 | View |
| 2025-10-27 | Letter To Shareholders Whose KYC Is Not Updated | View |
| 2025-10-14 | Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-10-10 | Press Release Pertaining To The Launch Of New High-Speed Isolator Based Line At Its Spokane Manufacturing Facility In The US By Jubilant Hollisterstier LLC USA A Wholly-Owned Subsidiary Of The Company | View |
| 2025-10-08 | Submission Of Communication Email Sent To Shareholders Whose Dividend(S) Remains Unpaid Pursuant To "Saksham Niveshak - 100 Days Campaign" | View |
| 2025-10-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |